Physician profile
Michael J Bykowsky
NPI 1245346196
$3,689.89
in general payments reported to CMS, 2019-2025
23 companies · $743 in 2025
The $743 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $1,402 · 2021: $203 · 2022: $670 · 2023: $184 · 2024: $77.25 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $1,298.92 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $547.22 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Optinose US, INC. | $447.95 | 2019-2025 | |
| Octapharma USA, INC. | $177.07 | 2022-2023 | Panzyga |
| Abbvie INC. | $147.82 | 2022-2023 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $144.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.31 | 2021-2025 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $115.58 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $114.61 | 2022-2025 | Ruconest |
| Galderma Laboratories, L.P. | $68.62 | 2025 | Nemluvio |
| Hospira, INC. | $62.37 | 2019-2022 | |
| Csl Behring | $53.12 | 2020-2025 | Hizentra |
| Biocryst US Sales Co., LLC | $44.72 | 2021-2022 | |
| Genentech USA, INC. | $43.19 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.32 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.94 | 2022 | |
| Ionis Pharmaceuticals, INC. | $24.21 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Covis Pharma Gmbh | $17.09 | 2022 | |
| Aytu Biopharma, INC. | $16.15 | 2025 | |
| Incyte Corporation | $14.22 | 2022 | |
| Pfizer INC. | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bykowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.